Lawson Kroeker Investment Management Inc. NE boosted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.0% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 98,088 shares of the biopharmaceutical company’s stock after purchasing an additional 925 shares during the period. Gilead Sciences makes up approximately 2.5% of Lawson Kroeker Investment Management Inc. NE’s portfolio, making the stock its 16th biggest holding. Lawson Kroeker Investment Management Inc. NE’s holdings in Gilead Sciences were worth $7,573,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of the business. Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in shares of Gilead Sciences in the second quarter worth $132,000. Brand Asset Management Group Inc. acquired a new stake in shares of Gilead Sciences in the second quarter worth $139,000. Wealthsource Partners LLC acquired a new stake in shares of Gilead Sciences in the second quarter worth $206,000. Aspen Investment Management Inc acquired a new stake in shares of Gilead Sciences in the first quarter worth $207,000. Finally, LFA Lugano Financial Advisors SA increased its position in shares of Gilead Sciences by 127.0% in the third quarter. LFA Lugano Financial Advisors SA now owns 2,760 shares of the biopharmaceutical company’s stock worth $213,000 after acquiring an additional 1,544 shares in the last quarter. 77.99% of the stock is currently owned by institutional investors.
Several equities research analysts have recently issued reports on the stock. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday. Cantor Fitzgerald assumed coverage on shares of Gilead Sciences in a research report on Monday, October 1st. They issued an “overweight” rating and a $87.00 price objective for the company. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Zacks Investment Research lowered shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 25th. Finally, Piper Jaffray Companies set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Eleven analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $88.24.
GILD opened at $73.59 on Friday. The firm has a market cap of $100.09 billion, a P/E ratio of 8.60, a PEG ratio of -3.92 and a beta of 1.01. Gilead Sciences, Inc. has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a quick ratio of 2.92, a current ratio of 3.00 and a debt-to-equity ratio of 1.23.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.56 by $0.35. The business had revenue of $5.65 billion during the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The business’s revenue was down 20.9% on a year-over-year basis. During the same period last year, the business earned $2.56 EPS. Equities analysts forecast that Gilead Sciences, Inc. will post 6.56 earnings per share for the current year.
The company also recently declared a quarterly dividend, which was paid on Thursday, September 27th. Investors of record on Friday, September 14th were issued a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date was Thursday, September 13th. Gilead Sciences’s payout ratio is 26.64%.
In related news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Tuesday, September 4th. The shares were sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at approximately $227,505,229.92. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 150,000 shares of company stock valued at $11,502,500. Company insiders own 1.16% of the company’s stock.
Gilead Sciences Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Recommended Story: Book Value Per Share – BVPS
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.